Pharmaceutical News

RSS

Study raises questions about educational efforts to increase knowledge of HPV vaccination

"Knowledge is power" is an old saying. Another cliché warns, "a little knowledge is a dangerous thing." When it comes to getting inoculated against the Human Papilloavirus (HPV), it seems that neither saying is true. In fact, according to a study by a multidisciplinary University of Pennsylvania research team, knowledge may in fact be a meaningless thing.

24 Sep 2014

Teens around the world frequently use OTC and prescription medications without doctor's order

Adolescents around the world are frequently using over-the-counter and prescription medications without a doctor's order, a risky practice that can lead to overuse and abuse and is often continued into adulthood, reveals a new review in the Journal of Adolescent Health.

24 Sep 2014

MT Services reports Actos drug cases, updates settlement news

MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today a primary focus on assisting plaintiffs of the after effects of the pharmaceutical drug Actos.

23 Sep 2014

Oxabact now recognized as potential treatment for Short Bowel Syndrome

SBS is a highly disabling malabsorptive condition. SBS is associated with significant morbidity and mortality, reduced quality of life and high healthcare costs.

23 Sep 2014

Anticonvulsant drug may help develop new class of antibiotics

McMaster scientists have found that an anticonvulsant drug may help in developing a new class of antibiotics.

23 Sep 2014

Amgen seeks FDA approval for leukemia drug blinatumomab

Amgen today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking approval for its investigational bispecific T cell engager (BiTE) antibody construct, blinatumomab.

22 Sep 2014

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV).

22 Sep 2014

SLU pediatric researcher to study efficacy of new hepatitis C drug treatment in children

After the success of a new drug treatment in adults with hepatitis C infection, a Saint Louis University pediatric researcher is testing the safety and efficacy of the medications in children.

21 Sep 2014

CDC urges all adults to get flu vaccination

Influenza vaccination coverage estimates show an encouraging upward trend overall, but coverage among healthy 18 to 64 year-olds has yet to top 40 percent, according to new data announced at a news conference held today by the National Foundation for Infectious Diseases.

19 Sep 2014

Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

19 Sep 2014

Rosuvastatin drug more effective among prediabetic patients, finds new study

Cardiovascular disease is the leading causes of death worldwide and high cholesterol plays a major role in accelerating its progression. Medical practitioners have turned to statins as a treatment to decrease cholesterol-carrying lipoproteins such as small dense lipoproteins (sdLDL), considered to be especially harmful.

19 Sep 2014

Rosuvastatin promotes bone growth in mice with achondroplasia symptoms

Skeletal dysplasia is a group of rare diseases that afflict skeletal growth through abnormalities in bone and cartilage. Its onset hits at the fetal stage and is caused by genetic mutations.

18 Sep 2014

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

MSD, known as Merck & Co., Inc. (NYSE: MRK) in the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development programme for omarigliptin, MSD’s investigational treatment for type 2 diabetes.

18 Sep 2014

Janssen announces availability of PREZCOBIX for Canadians living with HIV

Janssen Inc. announced today that PREZCOBIX (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. It is the first HIV treatment option available to patients that provides boosted darunavir in a single tablet.

17 Sep 2014

LABA-ICS combination therapy better than LABAs alone for COPD

Among older adults with chronic obstructive pulmonary disease (COPD), particularly those with asthma, newly prescribed long-acting beta-agonists (LABAs) and inhaled corticosteroid combination therapy, compared with newly prescribed LABAs alone, was associated with a lower risk of death or COPD hospitalization, according to a study in the September 17 issue of JAMA.

17 Sep 2014

New guidance can help physicians determine best oral blood thinners for patients

Physicians around the world now have guidance that can help them determine the best oral blood thinners to use for their patients suffering from blood clots in their veins, thanks to a patient of The Ottawa Hospital who asked his physician a question he couldn't answer.

17 Sep 2014

Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

Adding a common epilepsy drug to a morphine regimen can result in better pain control with fewer side effects. Moreover, the combination can reduce the dosage of the opioid needed to be effective, according to a team of pain researchers at Indiana University.

17 Sep 2014

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I).

17 Sep 2014

Combating prescription drug abuse: an interview with Mark Trudeau and Carmen Catizone

Prescription drug abuse is an extremely complex problem with no single solution. For example, the very same medications that are so critical for alleviating pain in legitimate patients could easily be diverted and misused by other people.

16 Sep 2014

Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information.

16 Sep 2014

Pharmaceutical News

Study raises questions about educational efforts to increase knowledge of HPV vaccination

Teens around the world frequently use OTC and prescription medications without doctor's order

MT Services reports Actos drug cases, updates settlement news

Oxabact now recognized as potential treatment for Short Bowel Syndrome

Anticonvulsant drug may help develop new class of antibiotics

Amgen seeks FDA approval for leukemia drug blinatumomab

EYLEA Injection gets approval in Japan for treatment of myopic CNV

SLU pediatric researcher to study efficacy of new hepatitis C drug treatment in children

CDC urges all adults to get flu vaccination

Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Rosuvastatin drug more effective among prediabetic patients, finds new study

Rosuvastatin promotes bone growth in mice with achondroplasia symptoms

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

Janssen announces availability of PREZCOBIX for Canadians living with HIV

LABA-ICS combination therapy better than LABAs alone for COPD

New guidance can help physicians determine best oral blood thinners for patients

Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

Combating prescription drug abuse: an interview with Mark Trudeau and Carmen Catizone

Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News